linjc16/ctgov huggingface dataset:
Behavioral Interventions to Target Self-Control

Study Overview
=================
Brief Summary
-----------------
Low self-control has been associated with a number of unhealthy behaviors with low treatment success. Alternative non-pharmacological approaches have the potential for enhancing self-control. This pilot study will investigate if the practice of yoga and/or health and wellness education improve self-control in the context of nicotine addiction, and will set the stage for larger clinical trials using behavioral interventions to supplement or replace existing treatments and increase the rates of recovery from disorders in which low self-control is a susceptibility factor.

Official Title
-----------------
Behavioral Interventions to Target Self-Control in Abstinent Nicotine Dependent Smokers

Conditions
-----------------
Tobacco Smoking

Intervention / Treatment
-----------------
* Behavioral: Yoga
* Behavioral: Education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: should smoke a minimum of 10 cigarettes/day be fluent speaking and reading English in good physical health intend to quit smoking capable of abstaining from smoking for 12-14 hours should have easy daily access to a computer and/or other internet-enabled device Exclusion Criteria: current alcohol or substance use disorder (except nicotine) pregnancy history of psychosis or bipolar disorder current use of a behavioral or pharmacologic tobacco treatment any untreated medical or psychiatric condition that might compromise their safety during participation in the study (e.g. high blood pressure, diabetes, BMI >35)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Yoga<br>Sequential movements in coordination to the breath cycle followed by seated and supine postures to release muscle tension. | Behavioral: Yoga<br> <br> |
| Placebo Comparator: Education<br>A series of 30-minute recordings focused on different aspects of healthy living (e.g. diet, stress). | Behavioral: Education<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time (minutes) to first smoke after 12-hour abstinence |  | Assessed 1 week after visit 1 during a 2-hour abstinence reinforcement session |
Microcirculation Evolution in Patients After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
We evaluated the impact on macrocirculatory hemodynamics and microcirculation in patients after cardiac surgery and compared the evolutions of those parameters between patients with tissue hypoperfusion and normal perfusion. Consecutive patients after cardiac surgery who required mechanical ventilation and for whom sublingual microcirculation measurements were possible enrolled.

Detailed Description
-----------------
We evaluated the impact on macrocirculatory hemodynamics and microcirculation in patients after cardiac surgery and compared the evolutions of those parameters between patients with tissue hypoperfusion and normal perfusion.

Official Title
-----------------
Microcirculation Evolution in Patients After Cardiac Surgery

Conditions
-----------------
Patients After Cardiac Surgery

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients after cardiac surgery. Patients whom sublingual microcirculation measurements were possible. Exclusion Criteria: moribund patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with normal lac<br> | Other: No intervention<br>* No intervention, regular therapy<br>|
| Patients with abnormal lac<br> | Other: No intervention<br>* No intervention, regular therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microcirculation | PPV and MFI | Extubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microcirculation, cardiac surgery
Health First-Study 2

Study Overview
=================
Brief Summary
-----------------
The current study was designed to investigate the influence of choice of exercise program on exercise adherence. The two exercise programs included 1) traditional exercise at a fitness centre or 2) lifestyle exercise-walking using a pedometer to track steps. Biological and psychological indicators were examined to investigate the effect of choice in a sample of sedentary adults.

Official Title
-----------------
Health First: Health and Psychological Outcomes of Physical Activity- Study 2

Conditions
-----------------
Exercise Adherence, Sedentary Adults, Lifestyle, Traditional

Intervention / Treatment
-----------------
* Behavioral: choice of exercise program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 25-65 year old adults sedentary (exercise less than twice per month in the last 4 months) Exclusion Criteria: physician non-consent too active (exercise more than twice per month in the last 4 months) participated in previous studies from this lab

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: choice of exercise program|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exercise, adherence, lifestyle, choice, autonomy
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
Varicella zoster virus is part of the herpesvirus group and causes chickenpox in exposed individuals. The majority of the population is seropositive for this virus. Reactivation of varicella zoster virus occurs in up to 30% of the general population over 60 years old. Solid organ transplant recipients receive lifelong immunosuppression drugs and are at great risk of reactivation of all herpesviruses including the varicella zoster virus regardless of age. The vaccine has been shown to be effective in preventing shingles in the general population. The investigators' purpose is to determine how well the vaccine works in patients on renal replacement therapy and post-transplant.

Official Title
-----------------
Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations

Conditions
-----------------
Kidney Transplant

Intervention / Treatment
-----------------
* Biological: Zostavax (Live attenuated herpes zoster vaccine)
* Biological: Placebo vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-65 years Listed or will likely be listed for live donor kidney transplant within one month Exclusion Criteria: 1. Previous receipt of Zostavax

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Live attenuated herpes zoster vaccine<br> | Biological: Zostavax (Live attenuated herpes zoster vaccine)<br>* 0.6 mL subcutaneous<br>* Other names: Zostavax;|
| Placebo Comparator: Placebo<br> | Biological: Placebo vaccine<br>* 0.65 mL subcutaneous<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immunogenicity |  | 6 months |
Laparoscopic Surgery Versus Robot Surgery for Right-side Colon Cancer: Short-term Outcome of a Randomised Clinical Trial

Study Overview
=================
Brief Summary
-----------------
The recent introduction of robotic surgical system has revolutionized the field of minimally invasive surgery. The investigators hypothesized that adoption of a robotic surgical system for patients with right-side colon cancer seems appealing because This system provides high-definition three-dimensional vision, eliminates physiologic tremor, and better ergonomics. This randomized controlled trial was designed to determine the safety and efficacy of robotic right hemicolectomy in comparison with laparoscopic right hemicolectomy.

Conditions
-----------------
Colon Cancer

Intervention / Treatment
-----------------
* Procedure: robot-assisted surgery
* Procedure: laparoscopic right-hemicolectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: primary cancer right-side located tumor (from cecum to proximal transverse colon) Exclusion Criteria: tumor with obstruction tumor with perforation clinically advanced tumor (T4 stage) tumor with distant metastases synchronous tumor

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RAP<br>individuals who underwent robot-assisted surgery for primary right-sied colon cancer | Procedure: robot-assisted surgery<br>* da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)<br>|
| Active Comparator: LAP<br>Individuals who underwent laparoscopic surgery for primary right-side colon cancer | Procedure: laparoscopic right-hemicolectomy<br>* Conventional laparoscopic procedures<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| surgical quality based on pathological examination |  | during perioperative period (1-30 days after operation) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication |  | during perioperative period ( 1-30 days after primary operation) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colon cancer, robot, laparoscopy, primary, right-side colon cancer, robot-assisted surgery
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation (OIC) in patients with non-cancer pain. Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis (IA) receive the treatment as follows: Patients on tegaserod 6 mg twice daily (b.i.d.) or 12 mg once daily (o.d.) in the core study will remain on the same dose in the extension (double-blind). Patients on placebo during the core study will receive tegaserod 12 mg o.d. (open-label) Patients who enter this study AFTER the core study interim analysis will receive the selected tegaserod dose regimen (open-label) determined by the core study IA.

Official Title
-----------------
A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain

Conditions
-----------------
Opioid-induced Constipation

Intervention / Treatment
-----------------
* Drug: Tegaserod


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has completed the 12 week double blind treatment of study CHTF919N2201 Exclusion Criteria: Planned discontinuation of opioids during the study. Development of any of the medical conditions listed as exclusion criteria for the CHTF919N2201 study. Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tegaserod|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long term safety of tegaserod |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline assessment of OIC symptoms, at week 24 and 52 |  |  | 
| Change from baseline assessment of opioid-induced mid/upper GI symptoms, at week 24 and 52 |  |  | 
| Patients' weekly assessment of intensity of pain for which opioids were prescribed, at week 24 and 52 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Opioid, constipation, tegaserod
Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease.

Study Overview
=================
Brief Summary
-----------------
Gastrointestinal endoscopy is a frequent procedure in the patients with advanced liver disease. It requires variable degree of sedation ranging from minimal sedation to general anesthesia aiming for relieving pain, anxiety, and bad memories of the procedure. In conscious sedation, patients are able to make purposeful responses to auditory and tactile clues, with maintenance of ventilatory and circulatory stability. while, in deep sedation, patients respond only to painful stimuli, and airway support is frequently required. At the level of general anesthesia, patients are unresponsive, and airway support is mandatory.

Detailed Description
-----------------
The aim of this study is to compare use of propofol or midazolam as sedative for patients with advanced liver disease presented for gastrointestinal endoscopy.

Official Title
-----------------
Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease.

Conditions
-----------------
Liver Diseases

Intervention / Treatment
-----------------
* Drug: Propofol
* Drug: Midazolam
* Drug: Fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged between 40 and 60 years old. With Child score B or C Presented for elective gastrointestinal endoscopy Exclusion Criteria: Emergent condition like hematemesis. Patients with moderate to severe hepatic encephalopathy. Patients with hepatopulmonary syndrome. Patients with known or suspected hypersensitivity to the used medication were also excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: M group<br>Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg | Drug: Midazolam<br>* Midazolam 3 mg i.v<br>* Other names: Dormicum;Drug: Fentanyl<br>* fentanyl 0.5 ug/kg<br>* Other names: Fantanyl;|
| Active Comparator: P Group<br>Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v | Drug: Propofol<br>* Propofol 1 mg/kg i.v<br>* Other names: propoven;Drug: Fentanyl<br>* fentanyl 0.5 ug/kg<br>* Other names: Fantanyl;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of sedation | Level of sedation using Ramsay sedation agitation score at before induction of sedation | 6 months |
Train New Examiners Via Modified Gingival Margin Plaque

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to train new examiners while testing two commercial products using our standard one-day brushing study regimen by measuring gingival margin plaque index.

Official Title
-----------------
Train New Examiners Via Modified Gingival Margin Plaque

Conditions
-----------------
Dental Plaque

Intervention / Treatment
-----------------
* Drug: Fluoride
* Drug: Triclosan/Fluoride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female volunteers 18-65 years of age Good general health Must sign informed consent form Must discontinue oral hygiene for 24-hrs.after initial appointment. Minimum of 20 natural uncrowned teeth (excluding third molars) must be present. No history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study. Exclusion Criteria: Subjects unable or unwilling to sign the informed consent form. Medical condition which requires pre-medication prior to dental visits/procedures Moderate or advanced periodontal disease or heavy dental tartar (calculus). 2 or more decayed untreated dental sites at screening. Other disease of the hard or soft oral tissues. Impaired salivary function (e.g. Sjogren's syndrome or head and neck irradiation). Use of medications that can affect salivary flow Use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1. Pregnant or nursing women. Participation in any other clinical study within 1 week prior to enrollment into this study. Use of tobacco products Subjects who must receive dental treatment during the study dates. Current use of Antibiotics for any purpose. Presence of an orthodontic appliance. History of allergy to common dentifrice ingredients. Immune compromised individuals (HIV, AIDS, immuno suppressive drug therapy)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: A<br> | Drug: Fluoride<br>* Brush twice daily<br>|
| Active Comparator: B<br> | Drug: Triclosan/Fluoride<br>* Brush twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Gingival Plaque Units | Scale 0 to 100% of tooth gingival margin covered by plaque. (0=no plaque, 100%=100% of the tooth's gingival margin is covered in plaque). | 1 day |
Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
Introduction Laparoscopic Sleeve Gastrectomy (LSG) is one of the most prevalent approaches to tackle obesity and its co-morbidities. The main complication following the LSG is Gastro-esophageal reflux disease (GERD), with most patients developing worsening symptoms of GERD, and a small number progressing to Barrett's esophagus. This retrospective analysis aims to assess the rate of GERD pre- and post- LSG as well as the rate of progression to Barrett's. Methods Data was collected from 1639 patients. 92 patients fit our inclusion criteria. Data was then analyzed and summarized against similar literature

Official Title
-----------------
Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study

Conditions
-----------------
Barrett Esophagus

Intervention / Treatment
-----------------
* Diagnostic Test: Laparoscopic Sleeve Gastrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients eligible to sleeve gastrectomy that had an EGD pre and 5 years post-op Exclusion Criteria: missing or implausible data, had multiple surgeries, and suffered from the common post-sleeve complications, such as leaks, strictures and hiatal hernias

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 36 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Laparoscopic Sleeve Gastrectomy|bariatric surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endoscopy performed on patients | endoscopy will be performed on patients 5 years after undergoing sleeve gastrectomy due to the fact that sleeve tends to lead to reflux which causes dysplasia of esophageal cells, which eventually can lead to barrett's esophagus and cancer. | 5 years |